These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Low dosage intravenous calcitriol bolus therapy in chronic hemodialysis patients].
    Author: Neyer U, Wöss E, Drexel H.
    Journal: Acta Med Austriaca; 1994; 21(5):129-32. PubMed ID: 7709710.
    Abstract:
    Severe secondary hyperparathyroidism in patients on chronic renal replacement therapy is still an immense problem, even after the introduction of the oral calcitriol therapy. Because the current first choice treatment--intravenous calcitriol-bolus application--fails to decrease parathyroidhormone (PTH) in some patients, we decided to monitor 22 chronic hemodialysis patients receiving low dose therapy with 3 x 1 micrograms calcitriol per week for a period of 6 months. After 6 months the PTH increased from 430 +/- 318 to 573 +/- 508 pg/ml (p < 0.05), the serum calcium from 2.14 +/- 0.22 to 2.31 +/- 15 mmol/l (p < 0.01). There was no significant change in serum phosphate, alkaline phosphatase (APH) and osteocalcin. The patients were divided into 2 groups according to their basal PTH-levels. Group 1 (n = 7, PTH < 200 pg/ml) showed a significant decrease of the PTH-levels from 99 +/- 38 to 61 +/- 53 pg/ml (p < 0.05). There was no significant change in serum calcium, phosphate, APH and osteocalcin levels. In group 2 (n = 15, PTH > 300 pg/ml) the PTH increased significantly (p < 0.05) from 585 +/- 287 to 812 +/- 439 pg/ml. No significant change was found for APH or osteocalcin. Calcium and phosphate levels increased significantly from 2.11 +/- 0.20 to 2.31 +/- 0.12 mmol/l (p < 0.01) and from 2.29 +/- 0.47 to 2.74 +/- 0.60 mmol/l (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]